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Abstract
Background Interleukin-15 (IL-15) promotes growth and
activation of cytotoxic CD8+ T and natural killer (NK) cells.
Bioactive IL-15 is produced in the body as a heterodimeric
cytokine, comprising the IL-15 and IL-15 receptor alpha
chains (hetIL-15). Several preclinical models support the
antitumor activity of hetIL-15 promoting its application in
clinical trials.
Methods The antitumor activity of hetIL-15 produced
from mammalian cells was tested in mouse tumor
models (MC38 colon carcinoma and TC-1 epithelial
carcinoma). The functional diversity of the immune
infiltrate and the cytokine/chemokine network within
the tumor was evaluated by flow cytometry, multicolor
immunohistochemistry (IHC), gene expression profiling
by Nanostring Technologies, and protein analysis by
electrochemiluminescence and ELISA assays.
Results hetIL-15 treatment resulted in delayed primary
tumor growth. Increased NK and CD8+ T cell tumoral
infiltration with an increased CD8+/Treg ratio were found
by flow cytometry and IHC in hetIL-15 treated animals.
Intratumoral NK and CD8+ T cells showed activation
features with enhanced interferon-γ (IFN-γ) production,
proliferation (Ki67+), cytotoxic potential (Granzyme B+) and
expression of the survival factor Bcl-2. Transcriptomics
and proteomics analyses revealed complex effects
on the tumor microenvironment triggered by hetIL-15
therapy, including increased levels of IFN-γ and XCL1
with intratumoral accumulation of XCR1+IRF8+CD103+
conventional type 1 dendritic cells (cDC1). Concomitantly,
the production of the chemokines CXCL9 and CXCL10
by tumor-localized myeloid cells, including cDC1, was
boosted by hetIL-15 in an IFN-γ-dependent manner. An
increased frequency of circulating CXCR3+ NK and CD8+ T
cells was found, suggesting their ability to migrate toward
the tumors following the CXCL9 and CXCL10 chemokine
gradient.
Conclusions Our results show that hetIL-15
administration enhances T cell entry into tumors,
increasing the success rate of immunotherapy
interventions. Our study further supports the incorporation

of hetIL-15 in tumor immunotherapy approaches to
promote the development of antitumor responses by
favoring effector over regulatory cells and by promoting
lymphocyte and DC localization into tumors through the
modification of the tumor chemokine and cytokine milieu.

Background
Immunotherapy has emerged as a valuable
strategy for the treatment of several type of
cancers.1 2 The clinical use of cytokines, antibodies targeting checkpoint inhibitors and
adoptive cell transfer is increasing, although
only a subset of patients benefits from
these approaches. The presence of tumor-
infiltrating effector T cells is considered
a favorable prognostic indicator in many
cancer types.3 In colorectal cancer, the infiltration of cytotoxic memory T cells within the
tumor center and invasive margin represents
an important predictor of survival.4–6 During
programmed cell death protein-1 blockade
treatment, higher numbers of CD8+ T cells
are found within the tumor of responder
patients.7 Several studies suggest that the
ratio of CD8+/Treg cells within the tumor
is an important predictor of cancer immunotherapy success.8 The presence of intratumoral conventional type 1 dendritic cells
(cDC1) has also been positively associated
with patient survival in multiple cancers.9 10
In preclinical models, abundance of cDC1
within the tumor microenvironment is associated with tumor regression and considered
critical for the success of T cell-based immunotherapies.11–13 cDC1 development requires
expression of the transcription factors Interferon regulatory factor 8 (IRF8) and Basic
leucin zipper transcriptional factor ATF-like
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3 (Batf3)14; they can be identified by surface expression of CD11c, the X-C Motif Chemokine Receptor 1
(XCR1)15 16 and the C-type lectin receptor DNGR-1.17
In non-lymphoid tissues, including tumors, cDC1 cells
also express integrinαE (CD103), whereas expression
of CD11b is low.10 12 18 The recruitment and retention
of cDC1s within the tumor are regulated by chemokines released by cancer cells, stroma and intratumoral
lymphocytes.11 19 The antitumoral activity of cDC1 relates
to their ability to cross-
present tumor antigens taken
up within the tumor microenvironment, and to initiate
primary T cell responses in the tumor-draining lymph
nodes,12 18 20 enhancing local cytotoxic lymphocyte
function.10 21 Additionally, cDC1 may contribute to the
recruitment of effector T cells by releasing Chemokine
(C-X-C motif) ligand 9 (CXCL9) and Chemokine (C-X-C
motif) ligand 10 (CXCL10),13 22 23 establishing a favorable chemokine gradient within the tumor. Analyses of
the tumor cytokine landscape have shown that interferon-γ (IFN-γ)24 and interleukin-15 (IL-15)25–27 signatures
are also associated with beneficial antitumor responses.
IL-15 is of great interest to the cancer immunotherapy
field due to its ability to promote survival and stimulate
several leucocyte subsets including natural killer (NK),
CD8+ and γδ T cells28 that possess antitumor properties.
In phase I clinical trials, Escherichia coli-derived single-
chain IL-15 was shown to expand NK and CD8+ T cells,
but the short plasma half-life29 and immunogenicity in
humans29 30 may limit the therapeutic use of this molecule. IL-15 expression in vivo requires the intracellular binding of IL-15 to IL-15 receptor α (IL-15Rα) in
producer cells.31–34 Indeed, we have reported that bioactive IL-15 in vivo comprises a complex of the IL-15 chain
with the IL-15Rα chain, which together form the IL-15
heterodimer (named hetIL-15).35 36 The two chains, IL-15
and IL-15Rα, are produced coordinately in the same cell
and associate rapidly in the endoplasmic reticulum36 37
due to their high binding affinity (kd ~10-11). hetIL-15
is then transported to the cell surface and, on proteolytic cleavage of IL-15Rα, released as bioactive soluble
heterodimeric molecule.35 36 38–40 hetIL-15 produced
from human HEK293 cells is well tolerated and bioactive
in both mice41 and rhesus macaques.42 43 Therapeutic
efficacy of hetIL-15 and molecules composed of parts of
IL-15 and IL-15Rα has been shown in preclinical cancer
models,40 44–48 and several molecules similar to hetIL-15
are currently being evaluated in cancer immunotherapy
clinical trials (NCT02452268 and49 50). We have shown
in the B16 melanoma model that hetIL-15 enhances the
survival, proliferation and antitumor effects of adoptively
transferred Pmel-1 cells without the need for lymphodepletion preconditioning, resulting in improved tumor
control and survival.47 Overall, hetIL-15 administration
is associated with increased proliferation of effector
memory T lymphocytes and NK cells expressing the cytotoxic serine protease Granzyme B (GzmB).47 However,
the mechanism(s) underlying promotion of antitumor
responses by IL-15 is still not completely understood.
2

The objectives of this study were to explore how hetIL-15
promotes lymphocyte entry into the tumor and to characterize the interactions between tumor-infiltrating lymphocytes (TILs) and other cell types through the analysis of
cytokines and chemokines affected by hetIL-15 therapy.

Methods
Mice
C57BL/6 mice were obtained from Charles River Laboratory and Envigo (Frederick, MD). IL-15 knock out (KO)
mice were purchased from Taconic. IFN-γ KO were kindly
provided by the Cancer Inflammation Program, National
Cancer Institute.
Mouse tumor models and hetIL-15 immunotherapy
Murine carcinoma-38 (MC38) colon carcinoma and
Tissue culture-1 (TC-1) lung epithelial cell-derived carcinoma cells were maintained in Dulbecco's Modified
Eagle Medium (DMEM) supplemented with 10% heat-
inactivated fetal bovine serum (Sigma), penicillin/streptomycin, essential amino acids and 4-(2-hydroxyethyl)-1
-piperazineethanesulfonic acid (HEPES). Animals aged
6–8 weeks received 1–2×105 tumor cells by subcutaneous
(SC) injection in the flank. Five days after inoculation of
tumor cells, tumor-bearing mice were randomized into
two groups, untreated and hetIL-15 treated. hetIL-15 was
purified from HEK293 cells (Admune Therapeutic LLC/
Novartis). For hetIL-15 treatment, mice received intraperitoneal (IP) injection of 3 µg (molar mass of IL-15)
of hetIL-1541 51 three times/week for a total of 4–8 injections. Tumor area (length x width) was measured every
2–3 days in a blinded fashion. To block protein secretion
from tumor cells in vivo, 100 µg brefeldin (Sigma) at a
concentration of 10 mg/mL were delivered intratumorally (IT), 30 min before sacrifice and tumor excision, in
some experiments.
Preparation of single cell suspension and flow cytometry
Excised tumors were cut into small pieces and digested
using the Tumor Dissociation Kit (130-096-730, Miltenyi
Biotec), as per manufacturer’s instructions. In some
experiments, CD8+ T cells were isolated from tumor cell
suspensions using Dynabeads FlowComp Mouse CD8 Kit
(ThermoFisher Scientific), as per manufacturer’s instructions. Spleens were dissociated using a 100 µm cell strainer
and washed to remove any remaining organ stroma. Cells
were washed and stained with a fixable viability dye (ThermoFisher Scientific) for 30 min at 4°C. Surface staining
was performed using antibodies for the following markers:
CD3 (145–2 C11), CD4 (RM4-5), CD8 (53–6.7), CD45
(30-F11), CD49b (DX5), CD64 (X54-5/7.1), CD19 (ID3)
from BD Biosciences; CD11c (N418), CD11b (M1/70),
MHC-
II (M114.15.2), XCR-1 (ZET), CXCR3 (CXCR3173) from Biolegend and CD103 (2E7) from ThermoFisher Scientific. For intracellular staining, cells were
fixed and permeabilized using the Foxp3 staining buffer
(ThermoFisher Scientific), following manufacturer’s
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instructions. Samples were stained with Ki67 (SOLA15)
and B-cell lymphoma-2 (Bcl-2) (3F11) from BD Biosciences; Foxp3 (FJK-
16s) and IRF8 (V3GYWCH) from
ThermoFisher Scientific; GzmB (GB11) and CXCL9
(MIG-
2F5.5) from Biolegend; and X-
C Motif Chemokine Ligand 1 (XCL1) (BAF486) from R&D Systems
followed by PE-Streptavidin (BD Biosciences). Cells were
acquired in a Fortessa flow cytometer (BD Biosciences).
Data analysis was performed using FlowJo software (Tree
Star, Ashland, Oregon, USA). Analyses of tumor immune
infiltrates were performed in two to three independent
experiments for each type of tumor.
In vitro stimulation of TILs
Tumor cell suspensions were seeded in 24-
well plates
in the presence of beads conjugated with α-CD3/CD28
antibodies (Dynabeads Mouse T Activator CD3/CD28,
11 452D, ThermoFisher Scientific) and incubated at
37°C in the presence of anti-CD107a antibody (1D4B, BD
Biosciences) and monensin (GolgiStop, BD Biosciences).
Similar cultures without antibody-stimulation were used
as negative controls. After 6 hours of incubation, cells
were harvested and stained for surface markers and intracellular IFN-γ (XMG1.2, BD Biosciences).
Immunohistochemistry
Immunohistochemistry (IHC) was performed as previously reported.52 After deparaffinization, 4.5 µm thick
sections were incubated with rabbit anti-CD3 (SP7, Abcam,
ab16669, 1:100), followed by treatment with tyramide-
fluorophore reagent (PerkinElmer, NEL791001KT;
Life Technologies, T20950) at 1:100 dilution in Amplification plus buffer (PerkinElmer, NEL791001KT) for
10 min at room temperature (RT) and washed in Tris-
Buffered Saline, 0.1% Tween®20 Detergent (TBS-
T)
and H20. Similar procedure was performed for the rat
anti-
CD8 (4SM15, ThermoFisher, 14-0808-82, 1:2000),
rat anti-
CD4 (4SM95, ThermoFisher, 14–9766, 1:200)
and rat anti-Foxp3 antibodies (FJK-16s, ThermoFisher,
145 773–82, 1:100) using an anti-
rat secondary HRP
(Vector Labs, MP-7444–15). After washes in TBS-
T,
4′,6-
diamidino-2-
phenylindole (DAPI) (Life Technologies, D1306, 1 mg/mL stock, 1:500 in Phosphate buffered saline (PBS)) was added to slides for 10 min at RT.
Slides were imaged at both 4 x, and 20 x using Vectra
imaging software (PerkinElmer), and the number of cells
were enumerated from the top nine hotspots images, to
provide equal weighting for each mouse, using inForm
analysis software (PerkinElmer).
Analysis of cytokine and chemokine levels in tumor lysates
Excised tumors were resuspended in T-Per Tissue Protein
Extraction Reagent (ThermoFisher Scientific) and
homogenized using 2.8 mm ceramic (zirconium oxide)
beads (Precellys Lysing kit) and Precellys Evolution
Homogenizer. Tumor lysates were recovered after spin at
13 000 rpm for 15 min at 4°C and analyzed for cytokine
levels using U-PLEX Biomarker group 1 mouse Assay (35

analytes; Meso Scale Diagnostics) and ELISAs specific for
the mouse chemokines XCL1 (ThermoFisher Scientific)
and CXCL9 (ThermoFisher Scientific), following manufacturers instructions.
Gene expression analysis by nCounter PanCancer immune
profiling panel
Tumors were mechanically disrupted in RLT buffer
(QIAGEN) using 2.8 mm ceramic beads (Precellys
Lysing kit) and Precellys Evolution Homogenizer. RNA
extraction was performed with RNeasy (QIAGEN)
including on-
column DNase I digestion, according to
the manufacturer’s instructions. nCounter PanCancer
Immune Profiling Panel (NanoString Technologies) was
used to monitor the expression of a panel of 780 genes
related to immuno-oncology. The mRNA molecules were
counted with the NanoString nCounter at the Laboratory of Molecular Technology (Advanced Technology
Program, Frederick National Laboratory). Analysis was
performed with a workflow written in R and through
a user interface developed on the Foundry Platform
(Palantir Technologies). Raw data were filtered to remove
low expressed genes, leaving 758 genes out of the original
780. To normalize data, log transformation and quantile normalization were applied. To define differentially
expressed genes, we run limma53 and set thresholds at
two-fold change and p<0.05 difference between groups
(adjusted p value following Bonferroni multiple comparison testing). Gene enrichment analysis on the Gene
Ontology (GO) database was subsequently performed on
the top 150 genes (sorted by t-statistic) using the Fisher’s
exact test (https://github.com/CCBR/l2p). Heatmaps
were represented as Z-score centered and rescaled. To
determine immune cell scores, the geometric mean of
the cell marker genes were calculated from normalized
gene expression values within each sample. Cell type gene
markers for cytotoxic cells and DCs were determined as in
Danaher et al.54
Statistics
Differences between untreated and hetIL-15 treated
mice were evaluated by a two-
tailed Mann-
Whitney U
test. Tumor areas were plotted as mean±standard error of
the mean (SEM) for each data point, and tumor growth
curves were compared using mixed-effects analysis of variance (ANOVA). The p values were corrected for multiple
comparisons using Holm-Sidak test. Prism V.8.1 software
package was used for analysis.

Results
hetIL-15 induces intratumoral accumulation of CD8+ T and NK
cells resulting in control of tumor growth
To address the role of endogenous IL-15 in tumor
growth, MC38 colon carcinoma cells were administered
SC to C57BL/6 wild type (wt) and age-matched IL-15
KO mice, and tumor development was monitored overtime. Tumors showed an accelerated growth in mice
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Figure 1 hetIL-15 delays tumor growth and promotes tumor-infiltrating lymphocytes proliferation and survival. Mice, implanted
with 2×105 MC38 cells at day −5, were randomized in two different treatment groups: hetIL-15 (blue traingle) and PBS (gray
square) administration. hetIL-15 (3 µg/injection/mouse) was injected IP three times per week. (A) Control mice (n=10) and
hetIL-15-treated mice (n=9) received eight injections, starting at day 0, and tumor growth was monitored overtime. Tumor size
measurements were performed every 2 to 3 days. Tumor area (length×width) mean±SEM for each time point are shown. Similar
results were obtained in three independent experiments. (B–G) MC38 tumor-bearing mice were sacrificed at day eight after
treatment with either PBS or hetIL-15 (1 day after the fourth administration). Tumor immune infiltrates were analyzed by flow
cytometry to determine: (B) frequency of tumor-infiltrating CD8+ T cells. Data of three independent experiments were combined;
(C) percentage of dividing tumor infiltrating CD8+T cells; (D) expression of the survival factor Bcl-2 in the tumor-infiltrating
CD8+ T cell population; (E) frequency of tumor-infiltrating NK cells; (F) percentage of dividing tumor infiltrating NK cells; (G)
intratumoral CD8+ T cells/Treg ratio for each treatment group. Bars represent mean±SEM. P values are from Mann-Whitney
U test. hetIL-15, heterodimeric interleukin-15; IP, intraperitoneal; MFI, mean fluorescence intensity; NK, natural killer; SEM,
Standard error of the mean.

lacking IL-15 compared with wt mice (online supplementary figure 1), suggesting that IL-15-dependent immune
mechanisms can limit the development of tumors. We
next used human cell-produced hetIL-15 treatment as
an anticancer immunotherapeutic drug in the MC38
colon carcinoma mouse model. hetIL-15 administration,
following a 2-week schedule with three injections/week
and a dose of 3 µg/injection by IP delivery, resulted in a
significant delay of tumor growth (figure 1A). Analysis of
the tumor immune infiltrate from untreated and hetIL-15
(day 8, 1 day after the fourth administration) treated mice
was performed by both flow cytometry (figure 1B–G)
and IHC (figure 2). hetIL-15 treatment increased the
number of intratumoral CD8+ T cells by ~3 x (figure 1B).
The proliferation rate of intratumoral CD8+ T cells in
4

untreated mice was ~50%–60%, suggesting rapid lymphocyte turnover in tumor sites. On hetIL-15 treatment, the
percentage of Ki67+ CD8+ T cells significantly increased
to ~80% (figure 1C). Tumor-infiltrating CD8+ T cells were
also characterized by a significant upregulation in the
expression of Bcl-2 in comparison to control mice, indicative of increased survival (figure 1D). Similar results were
also observed in the NK cells analyzed in MC38-bearing
mice (figure 1E–F). hetIL-15 treatment promoted a ~3
x increased accumulation of NK cells in the tumor sites
(figure 1E) and these NK cells showed significantly
higher proliferation rate in comparison to control mice
(figure 1F).
Favorable outcome in cancer immunotherapy treatments has also been linked to the ratio of CD8+ T cells
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Figure 2 CD8+ T cells accumulation and increased CD8+/Treg ratio in MC38 tumors from mice treated with hetIL-15. (A)
Immunohistochemistry staining of MC38 tumor sections from control (left panel) and hetIL-15-treated mice (right panel).
Analysis was performed at day eight after treatment with either PBS or hetIL-15 (1 day after the fourth administration). TILs
were monitored with CD3 (orange), CD4+ (red), CD8+ (yellow) and FOXP3 (green) antibodies. A representative image (×20
magnification) from one mouse/group is shown. Insert represents a ×4 magnification. (B–D) The number of CD8+ T cells per
mm2 (B), the number of Tregs per mm2 (C), and the ratio of CD8+ T cells/Treg cells (D). Data are from nine ×20 ‘hotspot’ fields
(containing the highest number of CD8+ T cells/mm2) per mouse. Six mice in each treatment group were analyzed. P values are
from Mann-Whitney U test. hetIL-15, heterodimeric interleukin-15; TILs, tumor-infiltrating lymphocytes.

to Tregs.8 For this reason, we determined the CD8+/Treg
ratio within the tumors from untreated and hetIL-15
treated mice. As previously reported in the B16 melanoma model,47 MC38 tumors were characterized by a
significant infiltration of Treg cells with a CD8+/Treg
ratio of ~2. hetIL-15 promoted a significant accumulation
of intratumoral CD8+ T cells resulting in a ~5 x increase in
the CD8+/Treg ratio (figure 1G).
The lymphocyte infiltrate in MC38 tumors was also
analyzed by IHC (figure 2). Staining of tumor sections
with antibodies against CD3, CD4, CD8 and Foxp3
confirmed that the lymphocytes isolated on in vitro digestion were of intratumoral origin rather than peripherally
associated with the excised tumors (figure 2A). Quantification of CD8+ T cells/mm2 (figure 2B) by IHC showed
a significant increase in the hetIL-15 group, with lymphocytes distributed throughout the tumor. In contrast,
hetIL-15 treatment did not affect the number of tumor-
infiltrating Tregs (figure 2C). As a consequence of CD8+
T cell expansion, a significant increase in the CD8+ T
cells/Treg ratio was also observed by IHC on hetIL-15
administration (figure 2D).
The anticancer efficacy of hetIL-15 was verified in the
mouse TC-1 carcinoma model using the same methods
(online supplementary figure 2A). hetIL-15 treatment
was associated with significantly increased intratumoral
CD8+ T cells, unchanged frequency of tumor infiltrating

Tregs and increased CD8+/Treg ratio (online supplementary figure 2B–F).
The systemic effects of hetIL-15 treatment were evaluated in MC38-bearing mice. hetIL-15 induced a significant
increase in the absolute number of CD8+ T and NK cells
in spleen (online supplementary figure 3A–D, respectively) with a significant upregulation in the expression
of Ki67+ cells (online supplementary figure 3B–E, respectively) and the survival marker Bcl-2 (online supplementary figure 3C).
Taken together, these data show that hetIL-15 sustains
proliferation and survival of lymphocytes both in tumor
and spleen, and verify the efficacy of hetIL-15 as anticancer immunotherapeutic agent.
hetIL-15 induces T cells with an effector-like gene signature
and promotes their cytotoxic functions
We performed gene expression analysis of MC38 tumors
using a panel of 780 immune-
oncology related gene
probes (Nanostring Technology). Tumors were excised
3 hours after the fourth hetIL-15 administration and
processed for mRNA isolation. Comparison of gene
expression identified several significantly overexpressed
genes in tumors recovered from hetIL-15-treated mice
(figure 3A). Gzmb and Gzma were the most upregulated
genes (~5 x, adjusted p<0.01). Xcl1, Prf1, Ctsw, CD69,
Klrc1, Ncr1 and Fasl were also significantly overexpressed
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Figure 3 Tumors from hetIL-15-treated mice comprise lymphocytes with an effector-like gene signature and enhanced
cytotoxic functions. (A) Gene expression analysis from MC38 tumors recovered from mice treated with either PBS (n=5) or
hetIL-15 (n=6) was performed by the Nanostring technology using a panel of 780 immune-oncology related gene probes.
The analysis was conducted at 3 hours after the fourth administration. Volcano plot depicts differentially expressed genes
between the two treatment groups, highlighting the upregulated genes (blue dots) on hetIL-15 treatment. To define differentially
expressed genes, we used one log2 change (vertical dotted lines) and p<0.05 (adjusted p value for multiple comparison;
horizontal broken line) difference between groups. (B–D) Tumor-resident CD8+ T cells (B), CD4+ T cells (C) and NK cells (D) were
analyzed for the expression of the cytotoxic marker GzmB by intracellular staining followed by flow cytometry. Dot plots from a
representative animal (upper panels) and the percentage of GzmB+ cells within each cell subset (bottom panel) are shown. (E)
Pie charts show the proportion of GzmB+Ki67-(red), GzmB+Ki67+(black), GzmB-Ki67+(gray) and GzmB-Ki67-(white) cells within
the total CD8+ T cell subset in tumor (left panel) and spleen (right panel) of hetIL-15 treated animals. (F–G) IFN-γ production and
degranulation (CD107) in tumor-infiltrating CD8+ T cells (F) and CD4+ T cells (G) on ex vivo stimulation with beads coated with
anti-CD3/CD28 antibodies. Dot plots show a representative animal from each group. Bars represent mean±SEM. P values are
from Mann-Whitney U test. hetIL-15, heterodimeric interleukin-15; IFN-γ, interferon-γ; NK, natural killer; GzmB, Granzyme B;
SEM, Standard error of the mean.
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in hetIL-15-treated mice (figure 3A). These upregulated
genes after hetIL-15 treatment represent an expression
signature that corresponds to activated TILs with cytotoxic phenotype. Nanostring analysis also identified additional functional pathway signatures, including signal
transducer and activator of transcription intracellular
signaling, T-cell receptor (TCR) recognition of cognate
antigen, IFNs signaling, increased metabolic rate and
immune cell chemotaxis (online supplementary figure
4).
To confirm the transcriptomic data, we analyzed
the GzmB content of TILs. Flow cytometric analysis
demonstrated that provision of hetIL-15 resulted in
higher proportion of tumor-infiltrating CD8+ and CD4+
T lymphocytes, as well as NK cells harboring GzmB in
comparison to untreated mice (figure 3B–D, respectively). Thus, hetIL-15 treatment led to a significant
accumulation of GzmB+ CD8+, CD4+ T and NK cells
per tumor. Similar results were obtained in the TC-1
tumor model (online supplementary figure 2G). We also
analyzed the GzmB content of splenic CD8+ T and NK
cells. In untreated animals, both CD8+ T and NK cells
were negative for GzmB, but on hetIL-15 administration, we observed a significant increase in the frequency
of lymphocytes harboring GzmB (online supplementary
figure 3F and G, respectively). Interestingly, we identified an intratumoral CD8+ T cell subset characterized
by the expression of GzmB and lack of Ki67 (figure 3E,
red) in hetIL-15 treated mice, but these cells were almost
completely absent within the spleen. These GzmB+Ki67CD8+ T cells are indicative of a terminally differentiated
cytotoxic phenotype and represented ~15% of the total
CD8+ T cells within the tumors (figure 3E). These data
indicate that hetIL-15 treatment preferentially induces
intratumoral accumulation of CD8+ T cells committed to
killing.
We also investigated the production of IFN-γ and
the degranulation activity (CD107+) by MC38 tumor-
derived T cells on ex vivo stimulation with beads coated
with α-CD3/CD28 antibodies. We found that ~10% of
CD8+ (figure 3F) and ~5% of CD4+ (figure 3G) tumor-
infiltrating T cells were able to secrete IFN-γ in untreated
control mice. Significant increase in the frequency of
IFN-γ+ CD8+ (~20%) and CD4+ (~10%) T cells was found
in tumors from the hetIL-15-treated group, suggesting
that hetIL-15 increases the production of IFN-γ within
the tumor. Similarly, we found an increased frequency of
degranulating CD107a+ CD8+ T cells in hetIL-15-treated
in comparison to control mice (figure 3F).
Overall, hetIL-15 administration shapes the tumor
microenvironment towards a Th1 profile, promoting activation and cytotoxic functional commitment in tumor-
resident T and NK cells.
cDC1 accumulate in tumors of hetIL-15 treated mice
Differential gene expression analysis showed that, in
addition to pathways related to NK and T cell activation
(online supplementary figure 4), hetIL-15 treatment

Figure 4 hetIL-15 enhances the production of XCL1
by tumor resident CD8+ T and NK cells. (A) Heatmap,
represented as Z-score centered and rescaled, of the
genes included in the GO:0002548 monocyte migration and
chemotaxis pathway from control (n=5) and hetIL-15-treated
(n=6) MC38-bearing mice. Significantly upregulated genes
in hetIL-15-treated mice in comparison to control mice are
depicted. (B) Evaluation of the chemokine XCL1 in MC38
tumors. The panel shows the tumor mRNA counts for Xcl1
as determined by the Nanostring technologies in both PBS
treated (n=5) and hetIL-15-treated (n=6) MC38-bearing mice.
(C) MC38 tumor lysates from either PBS-treated (n=11)
or hetIL-15-treated (n=10) mice were assessed for XCL1
concentration by ELISA. (D) Flow cytometric analysis of XCL1
production by NK and CD8+ T cells. Histogram overlays
show the expression of XCL1 by intratumoral NK and CD8+
T cells from a representative hetIL-15 (blue) and PBS (black)
treated mouse. Solid gray histogram shows non-staining
control. The XCL1 geometric mean fluorescent intensity
(MFI) in the tumor-infiltrating NK and CD8+ T cells from each
therapeutic group (n=6) are shown in the right panel. Bars
represent mean±SEM. P values are from Mann-Whitney U
test. hetIL-15, heterodimeric interleukin-15; NK, natural killer;
SEM, Standard error of the mean.

upregulated several intratumoral chemokines stimulating pathways related to myeloid cell migration and
chemotaxis (figure 4A, GO:0002548, p=0.039). Gene
expression analysis of the whole tumor revealed a ~4 x
increase in the expression of XCL1 mRNA on hetIL-15
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administration (figure 4B). Analysis of XCL1 protein
within the tumor was performed by ELISA at 6 hours
after hetIL-15 IP administration. A ~3 x increase in
XCL1 concentration was detected in tumor extracts from
hetIL-15 treated mice compared with tumors from PBS
treated mice (figure 4C). To identify the source of XCL1,
cell suspensions from MC38 tumors were analyzed for the
chemokine production in vivo. On day 8 after initiation
of treatment, mice received an IT injection of brefeldin
to block protein secretion in vivo. Tumors were excised
and isolated cells were analyzed by flow cytometry using
a panel of antibodies for the detection of NK and T cells
as well as XCL1. We found that both tumor-infiltrating
NK and CD8+ T cells produce XCL1 (figure 4D). hetIL-15
treatment resulted in a significant increase of XCL1
production by both cell subsets, as suggested by increased
XCL1 mean fluorescence intensity.
XCL1 has been linked to the tumor recruitment of
cDC1.11 16 55–57 These cells are known to support antitumor responses through the attraction, stimulation
and expansion of tumor-
specific CD8+ T cells.58 For
this reason, we evaluated the myeloid cell infiltrate in
MC38 tumors on hetIL-15 treatment. A previously established flow cytometry protocol allows the distinction
between cDC1, defined as CD45+MHCIIhighCD64-CD11c+CD11bdim, and other myeloid populations including
CD64+ macrophages and CD11bhigh conventional type 2
DC (cDC2).13 59 Additionally, expression of CD103, XCR1
and IRF8 on cDC1 has been linked to their ability to
cross-present antigens and stimulate efficient CD8+ T cell
responses.14–16 55 The strategy outlined in figure 5A was
used to identify cDC1 expressing XCR1, CD103 and IRF8
within CD45+ immune cells infiltrating the tumors. cDC1
constitute approximately 0.1% of intratumoral CD45+
leucocytes in MC38 tumors, in agreement with a previous
report.10 The expression of CD64 on these cells was ~4 x
reduced in comparison to MHCII+CD11b+ myeloid cells
(online supplementary figure 5A). Tumor-infiltrating B
cells represented between 0.05% and 0.6% of CD45+MHCII+ and did not stain positive for CD11c, XCR1 and
IRF8 (online supplementary figure 5B–D).
Treatment with hetIL-15 resulted in significantly
increased accumulation of cDC1 expressing CD103+XCR1+IRF8+ in MC38 tumors (figure 5B, left panel). Expression of the XCL1 receptor (XCR1) on this cell subset
suggests its ability to migrate toward the XCL1 gradient
within the tumors stimulated by hetIL-15 treatment.
Analysis of tumor-infiltrating cDC1 was also performed
in control and hetIL-15-treated mice bearing TC-1 carcinoma. Similarly, hetIL-15 treatment was associated with
~2 x increase in the number of cDC1 expressing CD103,
XCR1 and IRF8 localized within the tumors (figure 5B,
right panel). These results are in agreement with the
gene expression data revealed by transcriptomics (Nanostring Technology). Based on the differential expression
of cell type specific genes, cell scores were calculated for
different immune cell subsets as described in Material
and Methods. hetIL-15 treatment induced changes in the
8

composition of the tumor immune infiltrate (figure 5C).
hetIL-15 therapy was associated with a significant upregulation of the gene expression profile of both cytotoxic
cells (figure 5D) and DCs (figure 5E). In contrast to the
results obtained within the tumors, we observed a reduction in the frequency of XCR1+CD103+IRF8+ cDC1 in
the spleens of hetIL-15 treated animals compared with
control mice (online supplementary figure 3H).
Taken together, these data indicate that hetIL-15 treatment promotes the production of the chemokine XCL1
by intratumoral lymphocytes leading to increased tumor
infiltration by CD103+XCR1+IRF8+ cDC1.
hetIL-15 treatment stimulates CXCL9 and CXCL10 secretion by
intratumoral myeloid cells attracting CXCR3+ effector T cells
by an IFN-γ dependent way
The intratumoral accumulation of cDC1 and cytotoxic
lymphocytes promoted by hetIL-15 was accompanied
by increased IFN-γ production by T cells (figure 3)
resulting in higher IFN-γ concentration as measured in
tumor lysates by Meso Scale Discovery (MSD) quantitation (figure 6A). Differential gene expression analysis
showed an increase in IFN-γ mRNA (figure 6B) and
IFN-γ responsive genes and confirmed the enrichment
of this pathway within the tumor in hetIL-15 treated
animals (GO:0034341, p=0.049; figure 6B). The IFN-γ-dependent chemokines CXCL9 and CXCL10 were also
assessed in tumor lysates obtained from MC38 bearing-wt
and IFN-γ KO mice. Before hetIL-15 treatment, CXCL9
tumor concentration was slightly lower in IFN-γ KO
mice compared with wt mice, although this difference
did not reach statistical significance by one-way ANOVA
(figure 6C, left panel). CXCL10 levels were similar in
both strains of mice (figure 6C, right panel). hetIL-15
administration resulted in a ~3 x increase in the intratumoral concentration of both CXCL9 and CXCL10 only
in wt mice, with no changes being observed in IFN-γ KO
animals (figure 6C). To dissect the mechanism of intratumoral chemokine production in response to hetIL-15,
MC38-bearing wt and IFN-γ KO mice were treated with
brefeldin delivered IT to block protein secretion in vivo.
CXCL9 production in the excised tumors was analyzed
by flow cytometry using a mixture of antibodies targeting
both T and myeloid cells. We found that all tumor-
associated myeloid cell subsets analyzed (macrophages,
monocyte-derived DC and cDC1) produce CXCL9 in vivo
(figure 6D). hetIL-15 administration increased significantly the frequency of myeloid cells staining positive
for CXCL9 in wt mice (figure 6D). cDC1 were one of the
sources of CXCL9 (~8% and~2% in wt and IFN-γ KO mice,
respectively). The frequency of cDC1 cells producing
CXCL9 increased to ~25% in wt mice, but no changes
were observed in IFN-γ KO mice (figure 6E), indicating
that IL-15-stimulated CXCL9 production is IFN-γ-dependent. To confirm these data, single cell suspensions of
MC38 tumors were cultured for 6 hours in the presence
of either hetIL-15 or recombinant IFN-γ. Flow cytometry
analysis showed that cDC1 produced CXCL9 in response
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Figure 5 hetIL-15 treatment results in recruitment of XCR1+CD103+IRF8+ cDC1 into tumors. (A) Gating strategy for the
characterization of cDC1. (B) The frequency of tumor-infiltrating CD103+XCR1+IRF8+ cDC1 was determined in MC38 (left panel)
and TC-1 tumors (right panel) recovered from hetIL-15 or PBS-treated control mice. The number of CD103+XCR1+IRF8+ cDC1
cells in each tumor was normalized per million of cells present in the tumor suspension. The values from individual animals and
mean±SEM are shown. (C) Heatmap representing the immune cell composition of tumors on hetIL-15 treatment. Cell scores
were calculated for different immune cell subsets as described in material and methods. (D–E) RNA cell score for cytotoxic
cells (D) and dendritic cells (E) was calculated for tumors recovered from control (gray, n=5) and hetIL-15 (blue, n=6) treated
mice using Nanostring measurements as described in material and methods. Individuals animals and mean±SEM are shown. P
values are from Mann-Whitney U test. cDC1, conventional type 1 dendritic cells; hetIL-15, heterodimeric interleukin-15; SEM,
Standard error of the mean.

to hetIL-15 only from wt mice(figure 6F). As expected,
stimulation with recombinant IFN-γ restored the ability of
cDC1 from IFN-γ KO mice to produce CXCL9 to similar
levels observed in wt mice (figure 6F). These results are
in agreement with the measurements of intratumoral
chemokine levels and demonstrate that hetIL-15 stimulation of CXCL9 and CXCL10 production is, at least in
part, IFN-γ dependent.
CXCL9 and CXCL10 are key regulators of leucocyte
trafficking.60 Effector CD8+ T cells and a subset of NK cells

expresses CXCR3, the receptor for CXCL9, CXCL10 and
CXCL11, and they migrate following gradients of these
chemokines.13 23 61 We observed an increased presence of
CD8+ T lymphocytes and NK cells expressing CXCR3 in
blood of hetIL-15 treated wt mice (figure 6G). Evaluation
of CXCR3 expression in TILs was not possible, due to the
use of collagenase necessary for tumor processing. Overall,
these data support a mechanism of hetIL-15 action in
which lymphocyte trafficking to the tumor is controlled
by a gradient of the chemokines CXCL9 and CXCL10.
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Figure 6 hetIL-15 treatment stimulates secretion of CXCL9 and CXCL10 from tumor-localized myeloid cells in an IFN-γ
dependent fashion. (A) Intratumoral IFN-γ concentration measured by U-PLEX MSD in MC38 tumors excised from mice treated
with PBS (gray square; n=12) or hetIL-15 (blue triangle; n=12). (B) Heatmap for the genes included in the GO:0034341 IFN-γ
related pathway from control (n=5) and hetIL-15-treated (n=6) MC38-bearing mice. Heatmap is represented as Z-score centered
and rescaled. Significantly upregulated genes in hetIL-15-treated vs control mice are depicted. (C) Tumor concentration of
CXCL9 (left panel) and CXCL10 (right panel) in PBS- (gray squares) or hetIL-15-treated (blue triangles) wt and IFN-γ KO mice.
Bars represent mean±SEM. Data from one of two representative experiments are shown. (D) Dot plots showing the in vivo
production of CXCL9 by tumor-associated macrophages (defined as MHCII+CD64+ cells), monocyte-derived dendritic cells
(defined as MHCII+CD64-CD11c+CD11bhigh) and cDC1, treated with either PBS (upper panels) or hetIL-15 (lower panels). (E)
The frequency of intratumoral cDC1 cells producing CXCL9 is reported as the percentage of the total cDC1 in wt and IFN-γ KO
mice treated with PBS (gray square) or hetIL-15 (blue triangle). Bars represent mean±SEM from one representative experiment.
(F) CXCL9 production by intratumoral cDC1 recovered from MC38 tumor-bearing wt and IFN-γ KO mice. Cells were stimulated
ex vivo with hetIL-15 or IFN-γ and the ability to produce CXCL9 by cDC1 was evaluated by flow cytometry. Bars represent
mean±SEM. (G) The frequency of CXCR3+ CD8+ T cells and NK cells in blood of MC38-bearing mice treated with PBS (gray
square) or hetIL-15 (blue triangles) are shown as the percentage of the parental population. Bars represent mean±SEM. P
values are from Mann-Whitney U test. cDC1, conventional type 1 dendritic cells; hetIL-15, heterodimeric interleukin-15; IFN-γ,
interferon-γ; wt: wild type; KO, knock out; NK, natural killer; SEM, Standard error of the mean.
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Myeloid cells, including macrophages, monocyte-derived
DC and cDC1 are among the sources of these chemoattractants in the tumor in an IFN-γ dependent fashion.
Hence, the antitumor effects of hetIL-15 treatment are
linked to the increase of intratumoral lymphocyte infiltration by an IFN-γ-dependent mechanism.
Discussion
In this study, using the MC38 colon and TC-1 epithelial carcinoma mouse models, we demonstrate that
hetIL-15 orchestrates a multipronged immune response
that includes leucocyte expansion and trafficking to the
tumor, lymphoid-myeloid cell interactions and enhanced
cytotoxic responses through the induction of a favorable cytokine milieu that includes increased intratumoral production of specific chemokines. The increased
tumor accumulation of CD8+ T and NK cells observed
in hetIL-15 treated animals is the result of multiple and
concomitant effects, combining both expansion of tumor-
resident lymphocytes and recruitment of new immune
cells via chemokine gradients. hetIL-15 effects are both
direct and indirect and result in control of tumor growth.
hetIL-15 directly affects NK, CD8+ and CD4+ T cells within
the tumor promoting their proliferation, survival and
cytotoxic commitment, with high levels of IFN-γ production and upregulation of GzmA, GzmB and perforin.
Activated lymphocytes also secrete XCL1 in response to
hetIL-15 treatment, a chemokine likely responsible for
the enhanced intratumoral influx of cDC1 detected in
hetIL-15-
treated animals. cDC1, together with macrophages and monocyte-derived DC, are one of the sources
of the chemokines CXCL9 and CXCL10, previously
reported to direct trafficking of CXCR3+ effector lymphocytes to tumor sites.13 23 Importantly, CXCL9 and CXCL10
secretion by myeloid cells is not constitutive and requires
exposure to IFN-γ, suggesting a positive feedback loop
whereby the hetIL-15-dependent increase in intratumoral
XCL-1 and IFN-γ–producing lymphocytes enhances cDC1
recruitment and amplifies the CXCL9/10-directed intratumoral infiltration by CXCR3+ effector lymphocytes, as
summarized in the model depicted in figure 7.
The intratumoral leucocyte and cytokine composition orchestrates local interactions that result in either
enhancing or inhibiting antitumor immunity. A high
number of tumor-
infiltrating effector lymphocytes is
considered to be the most predictive biomarker for cancer
immunotherapy success.3 Effective immunotherapeutic
agents must promote an immune landscape capable of
recruiting T and NK cells within the tumor and enhance
their antitumor functions. In our study, tumors had an
accelerated growth in IL-15 KO mice, that lack NK cells
and have diminished memory CD8+ T cells, compared
with wt mice. Moreover, administration of hetIL-15
resulted in control of tumor growth in two different
cancer models in C57BL/6 mice. hetIL-15 therapy stimulated trafficking of CD8+ T and NK cells into the tumors,
and promoted proliferation (elevated Ki67 levels) and

Figure 7 Model representing the hetIL-15 triggered pathway
for tumor infiltration by lymphocytes and dendritic cells.
Activated CD8+ T and NK cells release IFN-γ and XCL1
in response to hetIL-15 treatment. The increased XCL1
concentration recruits cross-presenting cDC1 expressing
the chemokine receptor XCR1. cDC1 in tumors respond to
hetIL-15 by secreting the chemokines CXCL9 and CXCL10,
in an IFN-γ dependent manner. Systemic effects of hetIL-15
includes the enhanced frequency of circulating CXCR3+
CD8+ T and NK cells that can further infiltrate the tumor,
following the CXCL9 and CXCL10 chemokine gradient. cDC1,
conventional type 1 dendritic cells; hetIL-15, heterodimeric
interleukin-15; IFN-γ, interferon-γ; NK, natural killer.

survival (elevated Bcl-2) of the intratumoral lymphocytes.
TILs in hetIL-15-treated tumors were also characterized
by a gene expression pattern and phenotype of activated
cytotoxic lymphocytes. An important component of the
hetIL-15 mediated anti-tumor effects in our study was the
increased TILs and CD8+/Treg ratio in both MC38 and
TC-1 tumors, suggesting that hetIL-15 may be a favorable
immunotherapeutic intervention in tumors dependent
on Tregs-suppressive functions. Taken together, our data
suggest that the recruitment and activity of CD8+ T and
NK cells within the tumor are responsible for the potent
anticancer property of hetIL-15 therapy. These data are
in agreement with a recent study demonstrating that
endogenous soluble hetIL-15 is expressed in the tumor
niche and regulates the frequency of TILs.25 26
Using ‘omics’ approaches (Nanostring RNA analysis, and
Mesoscale in addition to the ELISA protein measurements),
we identified mechanisms responsible for the homing of
immune cells to the tumor niche in response to hetIL-15
therapy. hetIL-15 upregulated intratumoral Xcl1 mRNA
expression, and tumor lysates from hetIL-15 treated mice
were enriched in XCL1 chemokine. Immunophenotyping
analysis of intratumoral lymphocytes revealed activated
CD8+ T and NK cells as the source of this chemokine, in
agreement with previous reports.11 62 63 XCL1 increase associated with higher number of CD103+XCR1+IRF8+ cDC1.
XCL1 is often cosecreted with IFN-γ, CCL3, CCL4 and
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CCL5 by CD8+ T and NK cells and has emerged as a critical
component of the Th1 immune response against several
infections.64 Dorner et al16 showed that XCL1 is a selective
chemoattractant for murine splenic DCs highly efficient
in cross presentation. A recent report showed that cDC1
accumulation in transplantable mouse tumors depends
on tumor-infiltrating NK cells secreting the chemoattractants CCL5 and XCL1, whereas disruption of this mechanism resulted in cancer immune evasion.11 Additionally,
in certain human cancers, patient survival correlates with
the transcript level of CCL5 and XCL1, which were also
positively associated with the abundance of cDC1-like DCs
expressing CLEC9A, XCR1, CLNK and BATF3, highlighting
the clinical relevance of the findings. cDC1 uptake dead
tumor cells and cross-present tumor-derived peptides to
naïve CD8+ T cells in the draining lymph nodes, inducing
primary cytotoxic responses. Additionally, in this work, we
showed that cDC1 contribute also to the recruitment of
effector T cells expressing CXCR3, via the secretion of high
level of CXCL9, in agreement with a previous finding.13
IFN-γ plays a critical role in hetIL-15 mediated antitumor immunity. During hetIL-15 therapy, we observed
an upregulation of tumor IFN-γ, both mRNA and
protein, together with enhanced expression of the IFN-
inducible chemokines CXCL9 and CXCL10. A study
by Mikucki et al23 highlighted the mandatory role for
the CXCR3/CXCL9/CXCL10 axis in promoting T cell
entry into tumors. In agreement with these findings,
increased levels of CXCL9 and CXCL10 were reported
to be associated with higher density of tumor CD8+ T
cells, and to correlate with decreased metastatic burden
and improved survival in patients with multiple type of
cancers.65 66 In contrast, CXCL9, CXCL10 and CXCL11
were poorly expressed in ‘cold’ tumors lacking immune
infiltrate.67 Spranger et al13 showed that the exclusion of
CD103+ DCs from the tumor microenvironment lead to
alteration in the CXCL9/CXCR3 axis and to deficient
migration of transferred effector T cells to the tumor,
resulting in immunotherapy resistance in non-inflamed
tumors. In our study, we reported that cDC1 expressing
CD103, XCR1 and IRF8 accumulated at higher density
in hetIL-15 treated tumors. Together with other myeloid
subsets (macrophages and monocyte-
derived DC),
CD103+XCR1+IRF8+ cDC1 responded to hetIL-15 therapy
by producing CXCL9 and CXCL10 in an IFN-γ dependent fashion. The increased production of IFN-γ by intratumoral lymphocytes could enhance the intratumoral
expression of CXCL9 and CXCL10 and subsequent
recruitment of the hetIL-15-expanded pool of circulating
CXCR3+ lymphocytes, generating a positive amplification
loop that limits tumor growth.
A comparative analysis between tumor and spleen allowed
the identification of hetIL-15 effects restricted to the tumor
microenvironement. hetIL-15 resulted in an increased
accumulation of GzmB+Ki67- CD8+ T cells committed to
killing preferentially in tumors, supporting the hypothesis
that hetIL-15 acts in conjunction with antigen stimulation.
Indeed, in a model of adoptive cell transfer, we previously
12

reported that hetIL-15 treatment led to enrichment, in an
antigen-dependent manner, of Pmel-1 cells in B16 tumor
sites expressing gp100.47 Additionally, we observed a reduction in the frequency of splenic XCR1+CD103+IRF8+ cDC1
in hetIL-15 treated animals while their frequency significantly increased in tumors. The mechanism responsible for
this difference is currently under investigation. One possibility is their chemokine-driven mobilization towards tumor
sites on cytokine treatment.
Preclinical cancer studies support the use of IL-15 to
promote the development of antitumor responses by
increasing intratumoral lymphocyte infiltration, favoring
effector over regulatory cells, and by promoting DC-T cell
interactions. Several IL-15 formulations are in different
phases of clinical testing in cancer patients. It has been
reported that hetIL-15 shows pharmacokinetics and
bioactivity superior to single chain monomeric IL-15.41 In
comparison to single chain IL-15, hetIL-15 has a prolonged
serum half-life and is more bioactive on a molar basis.41
The superior bioactivity of IL-15 in the heterodimeric
formulation is mainly the result of the increased stability
of the heterodimeric protein in vivo. These properties
allow lower and less frequent dosing, decreasing toxicity.
Overall, our results show that hetIL-15 administration, by
changing the cytokine and cellular landscape within the
tumor, may be a general method to enhance T and cDC1
cell entry in tumors, increasing the success rate of immunotherapeutic interventions.
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